{"id":"https://openalex.org/W3018730765","doi":"https://doi.org/10.1017/s1092852920000565","title":"140 Effects of Long-Term Valbenazine on Tardive Dyskinesia in KINECT 4: Post Hoc Response and Shift Analyses","display_name":"140 Effects of Long-Term Valbenazine on Tardive Dyskinesia in KINECT 4: Post Hoc Response and Shift Analyses","publication_year":2020,"publication_date":"2020-04-01","ids":{"openalex":"https://openalex.org/W3018730765","doi":"https://doi.org/10.1017/s1092852920000565","mag":"3018730765"},"language":"en","primary_location":{"id":"doi:10.1017/s1092852920000565","doi":"https://doi.org/10.1017/s1092852920000565","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1092852920000565","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7EF654EF529E9874913970E7A5107F51/S1092852920000565a.pdf/div-class-title-140-effects-of-long-term-valbenazine-on-tardive-dyskinesia-in-kinect-4-post-hoc-response-and-shift-analyses-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7EF654EF529E9874913970E7A5107F51/S1092852920000565a.pdf/div-class-title-140-effects-of-long-term-valbenazine-on-tardive-dyskinesia-in-kinect-4-post-hoc-response-and-shift-analyses-div.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088564036","display_name":"Stephen R. Marder","orcid":"https://orcid.org/0000-0003-0288-309X","observed_orcids":["https://orcid.org/0000-0003-0288-309X"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen R. Marder","raw_affiliation_strings":["Professor, Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Professor, Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062212464","display_name":"Cynthia Comella","orcid":"https://orcid.org/0000-0001-7100-4701","observed_orcids":["https://orcid.org/0000-0001-7100-4701"]},"institutions":[{"id":"https://openalex.org/I1285301757","display_name":"Rush University Medical Center","ror":"https://ror.org/01j7c0b24","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285301757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cynthia L. Comella","raw_affiliation_strings":["Professor, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Professor, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL","institution_ids":["https://openalex.org/I1285301757"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088238884","display_name":"Carlos Singer","orcid":"https://orcid.org/0000-0001-7890-8391","observed_orcids":["https://orcid.org/0000-0001-7890-8391"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carlos Singer","raw_affiliation_strings":["Professor, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Professor, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL","institution_ids":["https://openalex.org/I145608581"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113065584","display_name":"Khodayar Farahmand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Khodayar Farahmand","raw_affiliation_strings":["Director, Head of Medical Communications, Neurocrine Biosciences, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Director, Head of Medical Communications, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108884150","display_name":"Roland Jimenez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roland Jimenez","raw_affiliation_strings":["Sr. Director, Clinical Development, Neurocrine Biosciences, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sr. Director, Clinical Development, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3160,"currency":"USD","value_usd":3160},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.04779784,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"25","issue":"2","first_page":"289","last_page":"289"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9800000190734863,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9800000190734863,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":0.004699999932199717,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.004600000102072954,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valbenazine","display_name":"valbenazine","score":0.996999979019165},{"id":"https://openalex.org/keywords/tardive-dyskinesia","display_name":"tardive dyskinesia","score":1.0},{"id":"https://openalex.org/keywords/abnormal-involuntary-movement-scale","display_name":"Abnormal Involuntary Movement Scale","score":0.8169999718666077},{"id":"https://openalex.org/keywords/long-term-treatment","display_name":"long-term treatment","score":0.5429999828338623},{"id":"https://openalex.org/keywords/antipsychotic-induced-movement-disorders","display_name":"antipsychotic-induced movement disorders","score":0.7110000252723694},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.6710000038146973},{"id":"https://openalex.org/keywords/schizoaffective-disorder","display_name":"schizoaffective disorder","score":0.8500000238418579},{"id":"https://openalex.org/keywords/mood-disorders","display_name":"mood disorders","score":0.7509999871253967},{"id":"https://openalex.org/keywords/vmat2-inhibitors","display_name":"VMAT2 inhibitors","score":0.7260000109672546},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.546999990940094},{"id":"https://openalex.org/keywords/shift-analysis","display_name":"shift analysis","score":0.8119999766349792},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.6420000195503235},{"id":"https://openalex.org/keywords/treatment-tolerability","display_name":"treatment tolerability","score":0.4449999928474426},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5270000100135803},{"id":"https://openalex.org/keywords/antipsychotic-exposure","display_name":"antipsychotic exposure","score":0.3490000069141388}],"concepts":[{"id":"https://openalex.org/C2779158372","wikidata":"https://www.wikidata.org/wiki/Q1546328","display_name":"Tardive dyskinesia","level":3,"score":0.8541389107704163},{"id":"https://openalex.org/C2780325297","wikidata":"https://www.wikidata.org/wiki/Q834047","display_name":"Schizoaffective disorder","level":3,"score":0.6681762933731079},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6630436778068542},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.6359354257583618},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5983390212059021},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.5346053838729858},{"id":"https://openalex.org/C2778261627","wikidata":"https://www.wikidata.org/wiki/Q2608695","display_name":"Movement disorders","level":3,"score":0.5271115899085999},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.509493887424469},{"id":"https://openalex.org/C83849319","wikidata":"https://www.wikidata.org/wiki/Q7295720","display_name":"Rating scale","level":2,"score":0.5078738331794739},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.49099043011665344},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4747498333454132},{"id":"https://openalex.org/C2776000289","wikidata":"https://www.wikidata.org/wiki/Q5133761","display_name":"Clinical Global Impression","level":4,"score":0.4594612121582031},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41523805260658264},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.2741881310939789},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.2736610174179077},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.23824438452720642},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.2021261751651764},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.10005760192871094},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C138496976","wikidata":"https://www.wikidata.org/wiki/Q175002","display_name":"Developmental psychology","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1017/s1092852920000565","doi":"https://doi.org/10.1017/s1092852920000565","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1092852920000565","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7EF654EF529E9874913970E7A5107F51/S1092852920000565a.pdf/div-class-title-140-effects-of-long-term-valbenazine-on-tardive-dyskinesia-in-kinect-4-post-hoc-response-and-shift-analyses-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1017/s1092852920000565","doi":"https://doi.org/10.1017/s1092852920000565","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s1092852920000565","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7EF654EF529E9874913970E7A5107F51/S1092852920000565a.pdf/div-class-title-140-effects-of-long-term-valbenazine-on-tardive-dyskinesia-in-kinect-4-post-hoc-response-and-shift-analyses-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320315137","display_name":"Neurocrine Biosciences","ror":"https://ror.org/05d84mm26"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3018730765.pdf","grobid_xml":"https://content.openalex.org/works/W3018730765.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4365511277","https://openalex.org/W3102302215","https://openalex.org/W3017497445","https://openalex.org/W2782831768","https://openalex.org/W2803665105","https://openalex.org/W3020103572","https://openalex.org/W2947122960","https://openalex.org/W3011351390","https://openalex.org/W2474667051","https://openalex.org/W2984880439"],"abstract_inverted_index":{"Abstract:":[0],"Study":[1],"Objective:":[2],"Valbenazine":[3],"(VBZ)":[4],"is":[5,435],"a":[6,23,54,162,222,229,256,322,397,406],"highly":[7],"selective":[8],"vesicular":[9],"monoamine":[10],"transporter":[11],"2":[12],"(VMAT2)":[13],"inhibitor":[14],"approved":[15],"for":[16,102,208,332,347,440],"the":[17,83,293,348],"treatment":[18,68,383,439],"of":[19,66,93,120,128,158,191,263,290,382,392],"tardive":[20],"dyskinesia":[21],"(TD),":[22],"persistent":[24],"and":[25,38,134,160,277,336,342],"potentially":[26],"disabling":[27],"movement":[28],"disorder":[29],"associated":[30],"with":[31,69,146,255,384,443],"prolonged":[32],"antipsychotic":[33],"exposure.":[34],"Post":[35],"hoc":[36],"response":[37,296,401,409],"shift":[39,417],"analyses":[40],"were":[41,137,194,328,351],"conducted":[42,207],"using":[43],"Abnormal":[44],"Involuntary":[45],"Movement":[46],"Scale":[47,114],"(AIMS)":[48],"data":[49],"from":[50,179,184,221,299],"KINECT":[51,77,393],"4":[52,78,153,394],"(NCT02405091),":[53],"long-term":[55,438],"open-label":[56,67],"study":[57,448],"in":[58,186],"which":[59],"participants":[60,80,238,264,291,310,395],"received":[61],"up":[62],"to":[63,88,106,131,148,165,181,228,304,321,424],"48":[64,198,246,327,380],"weeks":[65,381],"once-daily":[70,385],"VBZ":[71,139,386,434],"(40":[72,247,271,282,354,387],"or":[73,97,124,388,414],"80":[74,149,171,250,274,285,343,356,389],"mg).":[75,344],"Methods:":[76],"included":[79],"who":[81,311],"met":[82],"following":[84],"criteria:":[85],"ages":[86],"18":[87],"85":[89],"years;":[90],"DSM-IV":[91],"diagnosis":[92],"schizophrenia,":[94],"schizoaffective":[95],"disorder,":[96],"mood":[98],"disorder;":[99],"neuroleptic-induced":[100],"TD":[101,159],"\u22653":[103,224,317,421],"months":[104],"prior":[105],"screening;":[107],"stable":[108],"psychiatric":[109,133],"status":[110],"(Brief":[111],"Psychiatric":[112],"Rating":[113],"score":[115,189,223,230,269,316,323,404,412,420,425],"<50);":[116],"no":[117],"high":[118],"risk":[119],"active":[121],"suicidal":[122],"ideation":[123],"behavior.":[125],"Stable":[126],"doses":[127],"concomitant":[129],"medications":[130],"treat":[132],"medical":[135],"disorders":[136],"allowed.":[138],"dosing":[140],"was":[141,168,173,216,449],"initiated":[142],"at":[143,151,196,226,233,244,318,325,422,427],"40":[144,166,340],"mg,":[145,248,251,272,275,283,286,355],"escalation":[147],"mg":[150,167,172,341],"Week":[152,197,234,245,260,326,428],"based":[154,199],"on":[155,200],"clinical":[156],"assessment":[157,243],"tolerability;":[161],"dose":[163,257],"reduction":[164],"allowed":[169],"if":[170],"not":[174],"tolerated.":[175],"AIMS":[176,187,205,242,268,295,314,400,408,416],"responses,":[177],"ranging":[178],"\u226510%":[180,307],"100%":[182,302,331],"improvement":[183,220,270,281],"baseline":[185,227,423],"total":[188,267,403,411],"(sum":[190],"items":[192],"1-7),":[193],"analyzed":[195],"scoring":[201],"by":[202,451],"site":[203],"investigators.":[204],"shift,":[206],"each":[209],"item":[210,315,419],"(representing":[211],"7":[212],"different":[213],"body":[214],"regions),":[215],"defined":[217],"as":[218,329,352],"an":[219,240,313,415,436],"(moderate/severe)":[225],"\u22642":[231,324,426],"(none/minimal/mild)":[232],"48.":[235],"Results:":[236],"103":[237],"had":[239,265,279,312,396],"available":[241],"n=20;":[249],"n=83":[252],"[including":[253],"9":[254],"reduction]).":[258],"At":[259],"48,":[261],"94.2%":[262],"\u226530%":[266],"90.0%;":[273,284],"95.2%)":[276],"86.4%":[278],"\u226550%":[280],"85.5%).":[287],"The":[288],"percentage":[289],"meeting":[292],"remaining":[294,349],"thresholds":[297],"ranged":[298],"9.7%":[300],"(for":[301,306],"response)":[303],"97.1%":[305],"response).":[308],"In":[309],"baseline,":[319],"shifts":[320],"follows:":[330],"lips,":[333],"upper":[334],"extremities,":[335],"lower":[337],"extremities":[338],"(VBZ":[339],"Shift":[345],"rates":[346],"regions":[350],"follows":[353],"mg):":[357],"face":[358],"(100%":[359,364,369],"[9/9],":[360],"96.9%":[361],"[31/32]),":[362],"jaw":[363],"[10/10],":[365],"97.6%":[366],"[40/41]),":[367],"tongue":[368],"[11/11],":[370],"97.9%":[371],"[47/48]),":[372],"trunk":[373],"(87.5%":[374],"[7/8],":[375],"88.9%":[376],"[16/18]).":[377],"Conclusions:":[378],"After":[379],"mg),":[390],">85%":[391],"clinically":[398],"meaningful":[399],"(\u226530%":[402],"improvement),":[405,413],"robust":[407],"(\u226550%":[410],"(from":[418],"48).":[429],"These":[430],"results":[431],"suggest":[432],"that":[433],"appropriate":[437],"many":[441],"adults":[442],"TD.":[444],"Funding":[445],"Acknowledgements:":[446],"This":[447],"sponsored":[450],"Neurocrine":[452],"Biosciences,":[453],"Inc.":[454]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-05-01T00:00:00"}